DUOLITH® SD1 T-TOP »ultra«
Precision Focused Shockwave Therapy for Aesthetic, Regenerative & Sexual Medicine
The DUOLITH® SD1 T-TOP »ultra« is Storz Medical's flagship focused electromagnetic shockwave platform — a clinically validated, non-invasive technology that regenerates tissue at the biological level through precision mechanotransduction. Compact in form, comprehensive in reach.
Available exclusively through Evoskin
Focused ESWT
Electromagnetic Platform
0–65 mm
Adjustable Focal Depth
Up to 125 mm
Therapeutic Penetration
Non-Invasive
No Surgery · No Downtime
Precision Energy. Targeted Depth. Measurable Biology.
Focused shockwave therapy (ESWT) delivers high-energy acoustic pulses that converge at a defined focal point within tissue, generating intense mechanical stimulation at precise anatomical depths while leaving the surrounding structures undisturbed. This is categorically different from radial pressure wave devices, which scatter energy from the skin surface outward. Focused shockwaves are not surface tools. They are internal surgical-precision instruments — deployed non-invasively.
The DUOLITH® SD1 T-TOP »ultra« generates focused electromagnetic shockwaves through the SEPIA® handpiece — a system engineered to deliver exceptional pulse consistency, reproducible energy profiles, and adjustable focal zone depth from 0 to 65 mm, with therapeutic penetration reaching up to 125 mm. It is the same platform Storz Medical has refined across three decades of clinical use in urology, orthopedics, and aesthetics.
The molecular foundation
The biological effects are well-characterized. Focused shockwaves trigger mechanotransduction cascades in target tissue: upregulating VEGF (vascular endothelial growth factor), inducing neoangiogenesis, activating fibroblast and Schwann cell proliferation, modulating nociceptor hyperstimulation, and promoting the release of growth factors including eNOS, PCNA, and TGF-β1. These are not speculative mechanisms — they are the molecular foundation of decades of clinical evidence across multiple indications.
Focal Zone Depth
0–65 mm
Stand-off accessories mechanically shift the focal point to the exact tissue depth required. No estimation. No guesswork. Reproducible targeting across patients and sessions.
Therapeutic Penetration
up to 125 mm
Focused energy reaches tissue compartments inaccessible to radial devices — deep adipose layers, fascial planes, cavernous tissue, prostatic and pelvic floor anatomy.
Focused ESWT for Body Contouring & Skin Regeneration
Structural Tissue Change. Not Surface Treatment.
In aesthetic medicine, the distinction between surface treatment and structural tissue intervention is the difference between temporary improvement and lasting clinical results. The DUOLITH® SD1 T-TOP »ultra« operates in the structural tier. Focused shockwaves penetrate to the subcutaneous fat compartment, the subdermal connective tissue matrix, and deep fascial layers — initiating biological remodeling that begins at the cellular level and manifests clinically as improved contour, texture, firmness, and skin quality over a structured treatment course.
This is not thermal energy repackaged as “regenerative.” No heat is generated. No ablation occurs. The mechanism is purely mechanobiological: precision acoustic pulses translate into targeted cellular stress responses that upregulate repair pathways the body already possesses but cannot activate on its own in compromised tissue.
Cellulite & Fibro-Edematous Panniculopathy
Cellulite — histologically classified as fibro-edematous panniculopathy (FEP) — is a structural pathology involving fibrous septae that anchor the dermis to the deep fascia and create the characteristic surface dimpling visible in Grades II–IV. It is not resolvable by topical treatment or dietary intervention alone. The mechanical architecture of the fibrous septa must be disrupted at depth to achieve meaningful clinical change.
Focused shockwaves from the DUOLITH® SD1 T-TOP »ultra« deliver precisely that. High-energy focused pulses disrupt fibrous septae and calcified connective tissue tethers, simultaneously promoting neoangiogenesis in the surrounding hypoxic adipose tissue and activating lipolytic enzyme pathways in hypertrophic adipocytes. The result is measurable reduction in Nürnberger-Müller classification scores across a 6–8 session protocol, with progressive improvement continuing in the weeks following course completion.
Post-Liposuction Contour Irregularities
Skin surface irregularities following liposuction — including retraction bands, asymmetric contour depressions, and localized fibrosis — represent one of the most persistent challenges in body contouring correction. Focused shockwaves address the underlying fibrotic tissue directly, breaking down dense collagen adhesions, promoting ECM remodeling, and stimulating the regeneration of a more organized dermal architecture.
When deployed as a post-liposuction recovery protocol starting 4–6 weeks post-procedure, the DUOLITH® SD1 T-TOP »ultra« significantly reduces the time-to-resolution of contour irregularities and improves overall skin surface quality compared to observation alone. It represents a non-invasive corrective option that avoids the risks and recovery burden of revision surgery.
Scar Remodeling
Hypertrophic and fibrotic scars — surgical, traumatic, or post-liposuction — are characterized by disorganized collagen deposition, reduced vascular density, and impaired mechanosensing in dermal fibroblasts. Focused shockwaves address all three of these pathological features: they disrupt dense collagen cross-linking, promote angiogenesis within the avascular scar tissue, and restore mechanical signaling to quiescent fibroblasts, redirecting them toward organized Type I collagen synthesis.
The DUOLITH® SD1 T-TOP »ultra«'s adjustable focal zone depth allows precise targeting of scar tissue at its specific anatomical level — whether superficial dermal, subdermal, or extending into fascial planes — without disturbing surrounding healthy tissue.
Skin Tightening & Anti-Aging Body Protocols
Focused shockwave therapy stimulates fibroblast proliferation and collagen neosynthesis in the subdermal connective tissue layer, producing progressive improvement in skin firmness and elasticity across areas of laxity. Combined with the radial and vibratory wave modalities of the DUOLITH® SD1 T-TOP »ultra«, a complete structured skin tightening protocol can be delivered addressing the full thickness of the cutaneous and subcutaneous tissue stack.
Aesthetic Medicine Indications
| Parameter | Specification |
|---|---|
| Cellulite | Grade I–IV, all body zones; fibro-edematous panniculopathy (FEP) |
| Body contouring | Localized adipose tissue; abdominal, peritrochanteric, flanks, arms, submental |
| Post-liposuction | Contour irregularities, retraction bands, fibrotic adhesions, skin surface correction |
| Scar remodeling | Hypertrophic, fibrotic, surgical, traumatic scars; subdermal and fascial involvement |
| Skin tightening | Dermal laxity, subdermal connective tissue laxity; body and neck |
| Stretch marks | Striae distensae; periumbilical, breast, thigh, gluteal, arm |
| ECM remodeling | Collagen neosynthesis, fibroblast activation, elastin restoration |
Focused ESWT as a Regenerative Biophysical Platform
Activating the Body's Own Repair Architecture.
Regenerative medicine is defined by its goal: activating endogenous repair processes rather than substituting for them. Focused shockwave therapy is the only non-invasive biophysical technology with a documented molecular mechanism of tissue regeneration across multiple organ systems and tissue types. It does not replace biological repair — it amplifies it.
The DUOLITH® SD1 T-TOP »ultra« is particularly suited for integration into regenerative medicine protocols because its focused energy delivery can be precisely directed to the tissue requiring regenerative activation, at the specific depth where the pathological process is occurring. This allows the clinician to treat the lesion — not just the symptom.
Molecular Mechanisms of Tissue Regeneration
Neoangiogenesis
Focused shockwaves upregulate VEGF (vascular endothelial growth factor) and eNOS (endothelial nitric oxide synthase) expression in hypoxic and poorly vascularized tissue. New capillary formation follows, restoring oxygenation and nutrient delivery to tissue compartments impaired by chronic ischemia, fibrosis, or post-surgical disruption.
Stem Cell Recruitment
Mechanical energy from focused shockwaves activates resident stem cell populations — including CD34+ progenitor cells and mesenchymal stem cells — promoting their migration to the treatment zone and their differentiation into tissue-specific repair cells.
Growth Factor Release
ESWT triggers the release of PCNA (proliferating cell nuclear antigen), TGF-β1 (transforming growth factor), and bone morphogenetic proteins (BMP) — initiating cell proliferation, matrix deposition, and tissue architecture restoration.
Schwann Cell Activation
In neurogenic tissue dysfunction, focused shockwaves activate Schwann cell proliferation and axonal remyelination, contributing to nerve regeneration in conditions such as neuropathic erectile dysfunction and pudendal nerve injury.
“Focused shockwave therapy stands apart as the only non-invasive modality with a peer-reviewed molecular mechanism of tissue regeneration spanning vascular, neural, connective, and integumentary tissue — making the DUOLITH® SD1 T-TOP »ultra« the natural cornerstone of any serious regenerative medicine practice.”
Combination with PRP / Biologic Therapies
Focused ESWT and platelet-rich plasma (PRP) share complementary mechanisms and produce synergistic outcomes when combined. ESWT increases tissue vascularity and cell membrane permeability before PRP application, significantly enhancing platelet activation, growth factor distribution, and biological uptake at the treatment site. For practices offering ENDORET® PRP through Evoskin, the DUOLITH® SD1 T-TOP »ultra« creates the optimal tissue environment for PRP delivery — across aesthetic, sexual medicine, and musculoskeletal indications.
The combination of focused ESWT + PRP is increasingly considered the standard of care in regenerative sexual medicine protocols for ED and is also showing strong outcomes data in anti-aging body protocols and chronic musculoskeletal pathology.
Regenerative Medicine Indications
| Parameter | Specification |
|---|---|
| Tissue regeneration | Neoangiogenesis, fibroblast activation, ECM remodeling across multiple tissue types |
| Chronic wound healing | Ischemic wounds, venous ulcers, diabetic foot ulcers — ESWT restores vascular supply |
| PRP / biologic synergy | Pre-treatment to optimize tissue uptake of PRP and other biologic injectables |
| Nerve regeneration | Schwann cell activation, axonal remyelination; neuropathic conditions |
| Tendon regeneration | Collagen fibril reorganization; chronic tendinopathy and structural tendon repair |
| Post-surgical healing | Accelerated tissue repair and reduced fibrosis following aesthetic and reconstructive procedures |
Low-Intensity Focused ESWT (LI-ESWT) · Male & Female Sexual Health
Regenerative Sexual Medicine. Evidence-Based. Non-Invasive.
The application of low-intensity focused extracorporeal shockwave therapy (Li-ESWT) in sexual medicine represents one of the most compelling intersections of precision biophysics and regenerative biology in contemporary medicine. The DUOLITH® SD1 T-TOP »ultra« is the platform on which the majority of the published clinical evidence in this field has been generated — making it the device of record for practices committed to evidence-based sexual medicine.
Li-ESWT for sexual medicine operates at lower energy levels than orthopedic or aesthetic protocols, targeting the vascular, neurogenic, and fibrotic components of sexual dysfunction at their anatomical source. The SEPIA® handpiece's anatomically designed stand-off system allows precise, comfortable adaptation to the relevant pelvic and genital anatomy — a design feature that is clinically significant for both treatment reproducibility and patient compliance.
Erectile Dysfunction (ED)
Erectile dysfunction of vascular origin is the result of impaired arterial inflow and endothelial dysfunction in the penile microvasculature — the same pathological substrate addressed by Li-ESWT. Focused shockwaves applied to the corpus cavernosum and crura penis stimulate neoangiogenesis, restore endothelial function through eNOS upregulation, and activate Schwann cell proliferation in cases with neurogenic components.
The mechanism is not analgesic or symptomatic. Li-ESWT regenerates the vascular architecture of the penis — addressing the structural cause of ED rather than circumventing it. The clinical implications are significant: responders achieve functional erections without pharmacological support, and a meaningful subset of patients experience durable improvement beyond the active treatment course.
Clinical Evidence · Erectile Dysfunction · Multiple RCTs + Meta-analyses
A systematic review of 14 studies (N=833) concluded that Li-ESWT “may have the potential to become the first-line non-invasive treatment for ED patients” (Lu et al., European Urology, 2016). A prospective RCT (Olsen et al., 2014) demonstrated that 57% of men treated with Li-ESWT achieved satisfactory erections without medication after therapy. An Australian open-label study (Chung, BJU International, 2015) reported IIEF-5 improvement ≥5 points in 60% of patients; 67% reported satisfaction level 4/5; 80% would recommend the treatment to others.
Induratio Penis Plastica / Peyronie's Disease (IPP)
Peyronie's disease is an acquired fibrotic disorder of the tunica albuginea characterized by plaque formation, penile curvature, and pain during erection. It disproportionately impacts quality of life, sexual function, and psychological well-being, and is significantly underdiagnosed and undertreated in aesthetic and integrative medicine settings.
Focused shockwaves applied to the penile plaque activate fibroblast remodeling, promote fibrinolytic activity, and induce apoptosis of pathological myofibroblasts — the cellular mediators of plaque formation. Published data demonstrate measurable reduction in plaque volume, improvement in curvature angle, elimination of erection pain, and improved erectile function across a structured 5–8 week protocol.
Clinical Evidence · Induratio Penis Plastica · Prospective RCT + Long-Term Follow-Up
A prospective, randomized, double-blind, placebo-controlled study (Palmieri et al., European Urology, 2009; N=100) demonstrated that ESWT eliminates pain and significantly improves erectile function and quality of life at 12 and 24 weeks. A pilot study (Michel et al., Journal of Endourology, 2003) reported that erection pain disappeared in 15/17 patients after a 5-week protocol; 15 patients were able to achieve satisfactory intercourse post-treatment (vs. 6 pre-treatment). A 2017 systematic review (Fojecki et al., World Journal of Urology) confirmed ESWT eliminates pain in IPP patients.
Chronic Pelvic Pain Syndrome (CPPS)
Chronic pelvic pain syndrome in men — also classified as chronic abacterial prostatitis (Category IIIB) — is characterized by persistent perineal and pelvic pain, voiding symptoms, and sexual dysfunction. It affects predominantly men between 35 and 45 years and remains one of the most challenging conditions to manage pharmacologically, with significant impact on quality of life and sexual function.
Li-ESWT applied perineal to the prostate and pelvic floor targets the inflammatory and neurogenic components of CPPS through two complementary mechanisms: hyperstimulation of pain receptors, blocking afferent pain transmission; and modulation of central pain sensitization. The non-invasive protocol is repeatable, has no documented side effects, and demonstrates clinical durability across multiple follow-up assessments.
Clinical Evidence · CPPS · RCTs with Active vs. Placebo Control
A randomized, double-blind, placebo-controlled study (Zimmermann et al., European Urology, 2009) demonstrated statistically highly significant improvement in pain, quality of life, and urinary conditions in the ESWT group versus placebo. Results of a further RCT (Vahdatpour et al., ISRN Urology, 2013) and a 2016 systematic review (Fojecki et al., World Journal of Urology) confirmed ESWT as a safe and effective short-term treatment for CPPS.
Vulvodynia
Vulvodynia is defined as chronic vulvar pain or discomfort without identifiable cause. It is more common than clinical awareness reflects, significantly impacts sexual function and quality of life, and is notoriously resistant to pharmacological management. The DUOLITH® SD1 T-TOP »ultra« offers a non-pharmacological, repeatable, evidence-based treatment approach backed by prospective randomized controlled data.
Focused ESWT applied to the vulva and perineum blocks nociceptive afferent transmission through hyperstimulation analgesia and modulates central sensitization at the level of the spinal dorsal horn. The clinical result is a durable reduction in pain perception — not temporary masking, but neurological recalibration that persists through post-treatment follow-up.
Clinical Evidence · Vulvodynia · Prospective RCT, Placebo-Controlled
A prospective, randomized, double-blind, placebo-controlled study (Hurt et al., European Journal of Physical and Rehabilitation Medicine, 2020; N=61) demonstrated pain reduction >30% in the treatment group using VAS, with large effect size (VAS: 0.883). Pain reduction was sustained at all follow-up assessments (1, 4, and 12 weeks post-treatment). No significant differences observed in the placebo group.
Dyspareunia
Dyspareunia — pain during or after sexual intercourse — is a distressing and prevalent condition with multiple etiologies including provoked vestibulodynia, vulvar atrophy, and pelvic floor hypertonicity. It significantly impairs sexual health, relational wellbeing, and quality of life, and is frequently undertreated due to limited non-invasive options in clinical practice.
Focused ESWT applied to the perineum and vulvar vestibule targets the peripheral nociceptive and neurogenic mechanisms underlying dyspareunia, modulating C-fiber and Aδ-fiber afferent pain signaling and reducing local inflammatory mediator activity. The same research group that validated ESWT for vulvodynia extended their protocol to dyspareunia with equivalent results.
Clinical Evidence · Dyspareunia · Prospective RCT, Placebo-Controlled
A prospective, randomized, double-blind, placebo-controlled study (Hurt et al., Annals of Physical and Rehabilitation Medicine, 2021; N=61) reported pain reduction >30% in the ESWT group using both VAS and Marinoff Dyspareunia Scale. Marinoff Scale effect size: 0.825. Results were sustained across all follow-up time points (1, 4, and 12 weeks post-treatment).
Sexual Medicine — Male Protocol
ED / IPP / CPPS
6–12 sessions of 15–20 minutes, weekly. SEPIA® handpiece with anatomically shaped stand-off applied to corpus cavernosum, crura, and perineum. Can be combined with PRP, hormone optimization, and lifestyle protocols.
Sexual Medicine — Female Protocol
Vulvodynia / Dyspareunia
4–6 weekly sessions of ~15 minutes. SEPIA® handpiece applied to vulvar and perineal regions. Non-invasive, no sedation required, no downtime. Can be combined with PRP, topical, and pelvic floor protocols.
FDA-Cleared Focused ESWT for Musculoskeletal Disorders
Proven Across Orthopedics. Extended Into Medicine.
The DUOLITH® SD1 T-TOP »ultra«’s clinical credibility in aesthetic, regenerative, and sexual medicine rests in part on its 30-year evidence base in orthopedics — the discipline where focused ESWT was first rigorously studied and where it is FDA-cleared for clinical use. Plantar fasciitis, calcific tendinitis of the shoulder, lateral epicondylitis, Achilles tendinopathy, and chronic myofascial pain syndrome are among the orthopedic indications with the strongest published evidence for ESWT efficacy.
For aesthetic medicine and integrative practices offering sports medicine, musculoskeletal rehabilitation, or regenerative orthopedics as part of their service model, the DUOLITH® SD1 T-TOP »ultra« provides the same evidence-based focused shockwave platform across all disciplines — maximizing device utilization, ROI, and service breadth without requiring additional capital investment.
- FDA-cleared: Extracorporeal Shock Wave Treatment (ESWT) for heel pain / chronic proximal plantar fasciitis
- Calcific tendinitis of the rotator cuff (supraspinatus)
- Lateral epicondylitis (tennis elbow)
- Achilles tendinopathy and insertional Achilles pathology
- Chronic myofascial pain syndrome and trigger point treatment
- Stress fractures and delayed bone healing
STORZ MEDICAL · FOCUSED ELECTROMAGNETIC SHOCKWAVE HANDPIECE
SEPIA® — The Precision Instrument Behind Every Protocol.
The SEPIA® handpiece is the clinical core of the DUOLITH® SD1 T-TOP »ultra« platform. Designed by Storz Medical in Switzerland, it represents the current state of the art in focused electromagnetic shockwave delivery for medical practice. Every element of its design serves clinical function: the cable flexibility reduces fatigue across extended sessions; the integrated handpiece display eliminates console-referencing during treatment; the stand-off system provides mechanical, reproducible depth targeting; and the coil replacement architecture minimizes service downtime and total cost of ownership.
The SEPIA® handpiece is compatible with all DUOLITH® SD1 »ultra« system configurations, and is the standard handpiece across the URO (sexual medicine), orthopedic, and aesthetic applications of the platform. This cross-indication compatibility means that a single handpiece investment serves the full clinical scope of the DUOLITH® SD1 T-TOP »ultra«.
“The SEPIA® handpiece is designed so that the treatment is always carried out directly at the patient — an important criterion for everyday clinical practice. Frequency and energy level are adjustable directly on the handpiece, and all the important control elements are integrated into the handpiece.”
Technical Specifications
| Parameter | Specification |
|---|---|
| Wave type | Focused electromagnetic shockwave |
| Focal zone depth | 0 – 65 mm (mechanically adjustable via stand-off accessories) |
| Therapeutic penetration | Up to 125 mm |
| Energy range | 0 – 0.55 mJ/mm² |
| Controls | Fully integrated into handpiece display (frequency, energy, pulse count) |
| Cable design | High-flexibility cable — fatigue-free, uninterrupted patient-side operation |
| Stand-off system | Multiple stands-off included; anatomically shaped stand-off for sexual medicine |
| Coil replacement | User-replaceable electromagnetic coil — no service visit required |
| Compatibility | Compatible with all DUOLITH® SD1 »ultra« system configurations |
| Optional 10" touchscreen | USB-connected tablet with patient management, protocol library with videos + images, Visible Body® digital anatomy atlas |
| System dimensions | 16.8 × 5.7 × 13.4 in (W × H × D) — compact tabletop footprint |
30 Years of Published Evidence. One Platform.
The clinical evidence base supporting the DUOLITH® SD1 T-TOP »ultra« spans over three decades of peer-reviewed research across urology, sexual medicine, dermatology, regenerative medicine, and orthopedics. The following represents a condensed reference for the most clinically relevant published work across the indications covered in this document.
| Indication | Key Evidence |
|---|---|
| Erectile Dysfunction (ED) | Multiple systematic reviews and meta-analyses confirm efficacy. Li-ESWT named potential “first-line non-invasive treatment” (Lu et al., European Urology, 2016). 57% of patients achieved erection without medication (Olsen et al., 2014). IIEF-5 improvement ≥5 points in 60% of patients (Chung, BJU International, 2015). |
| Peyronie’s Disease (IPP) | Prospective RCT: significant improvement in VAS pain, IIEF-5, and QoL at 12 and 24 weeks (Palmieri et al., European Urology, 2009). Pain resolved in 15/17 patients; 15/24 achieved satisfactory intercourse post-treatment (Michel et al., 2003). 2017 systematic review confirms pain elimination. |
| CPPS — Male | Randomized, double-blind, placebo-controlled study: highly significant improvement in pain, QoL, and urinary conditions (Zimmermann et al., European Urology, 2009). Results confirmed by Vahdatpour et al. (ISRN Urology, 2013) and a 2016 systematic review. |
| Vulvodynia | Prospective RCT: VAS pain reduction >30%, large effect size (0.883). Sustained at 1, 4, and 12 weeks post-treatment (Hurt et al., EJPRM, 2020; N=61). |
| Dyspareunia | Prospective RCT: Marinoff Scale reduction >30%, effect size 0.825. Sustained at all follow-up time points (Hurt et al., Annals of Physical and Rehabilitation Medicine, 2021; N=61). |
| Plantar Fasciitis | FDA-cleared indication. High-quality evidence supporting Li-ESWT as non-surgical treatment for chronic proximal plantar fasciitis. |
All referenced studies are available through the Storz Medical Shock Wave Portal (shockwaveportal.com) and the Evoskin clinical resources library. Consult Evoskin’s clinical team for full bibliography, including specific protocols used in each study.
A three-decade platform, trusted worldwide
30+ Years
Of refined clinical use across urology, orthopedics, and aesthetics.
Focused
Electromagnetic energy that converges precisely at depth.
Non-Invasive
No heat, no ablation, no downtime — purely mechanobiological.
Evidence-Based
The platform of record for peer-reviewed ESWT clinical data.
Add Focused Shockwave to Your Practice.
Contact Evoskin to schedule a DUOLITH® SD1 T-TOP »ultra« demonstration, discuss financing, or enroll in Evoskin Academy’s focused ESWT training program.